In the case of Upshaw–Schulman syndrome, or TTP, which consists in a congenital deficiency of ADAMTS13, a proteolytic regulator of vWF levels, plasma or recombinant ADAMTS13-based replacement therapy has been suggested as an appropriate treatment. The gene discussed is ADAMTS13; the disease is thrombotic thrombocytopenic purpura.